Verisante Technology: (OTC: VRSEF)
$0.38
0.00 (0.16%)
Volume 2,500
May 22 03:04 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 0.38 - 0.38 |
| 52wk Low - High | 0.37 - 0.66 |
| Previous Close | 0.38 |
| Avg. Volume | 27,107 |
| Industry | MED/DENTAL-SUPP |
| Market Cap | 22.34 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.31 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
121 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | NA |
| EPS Last Year | NA |
| Expected Earnings Growth | NA |
Company Description
Verisante Technology, Inc. operates as a medical device company engaged in the development of innovative systems for the early detection of cancer. It develops and offers a range of compact, non?invasive cancer detection devices for many of the most common cancers, including gastro?intestinal, colorectal and cervical cancers. The Company's Verisante Aura series is a novel multimodality imaging and spectroscopy system designed to aid in the early detection of skin cancer. Other product offered by the company includes Verisante Core series and Authenticare- a pre-production prototype of a pharmaceutical tablet analyzer for the authentication of solid dosage pharmaceuticals. Verisante Technology, Inc. is based in Vancouver, British Columbia.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| LUXOTTICA ADR | LUX | 54.12 | |
|
| ALPHATEC HLDGS | ATEC | 1.91 | |
|
| BECTON DICKINSO | BDX | 100.02 | |
|
| CONMED CORP | CNMD | 33.28 | |
|
| COOPER COS | COO | 107.22 | |
|
| STERIS CORP | STE | 45.03 | |
|
| WEST PHARM SVC | WST | 67.34 | |
|
| ALIGN TECH INC | ALGN | 37.30 | |
|
| BARD C R INC | BCR | 105.28 | |
|
| BIO REFERNC LAB | BRLI | 31.07 | |
|
Sector:Medical>> Industry:MED/DENTAL-SUPP
COMPARE TICKER vs. Its Peers
Zacks Commentary
VRSEF: Meaningful Progress on Several Fronts
Feb 28, 2013
VRS.V: Q3 Update / New Core Data
Dec 03, 2012
Field Testing Ongoing / Rodman Presentation
Sep 18, 2012
On-Track For 2012 Launch
Jul 26, 2012
Report Not Available
Financials
| EPS TTM | NA |
| Sales | NA |
| Net Income | NA |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
Verisante Completes Private Placement - Marketwire
May 17, 2013
Verisante Completes Private Placement - Marketwire Canada
May 17, 2013
Verisante Aura is Named a 2013 Bronze Edison Award Winner - Marketwire
Apr 26, 2013
Verisante Aura is Named a 2013 Bronze Edison Award Winner - Marketwire Canada
Apr 26, 2013
Verisante Announces Official Launch of Aura in Canada, Provides Operational Update - Marketwire Canada
Apr 16, 2013
Verisante Announces Official Launch of Aura in Canada, ProvidesOperational Update - Marketwire
Apr 16, 2013
Verisante Technology announces official launch of Aura in Germany - Datamonitor
Mar 27, 2013
Verisante Announces Official Launch of Aura in Germany - Marketwire
Mar 20, 2013
Broker Recommendations
| Current ABR | NA |
| ABR (Last Week) | NA |
| # of recs in ABR | NA |
| Average Target Price | NA |
| Industry Rank by ABR | 121 out of 265 |
| Rank in Industry | NA |
